EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum



Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum



Gaoxiong Yi Xue Ke Xue Za Zhi 7(3): 126-135



To evaluate the clinical efficacy of recombinant human erythropoietin (EPO) and its influencing factors in the treatment of anemia in hemodialysis (HD) patients, 17 chronic stable HD patients (10 males, 7 females; mean age: 46.0 +/- 2.6 years) with severe anemia were enrolled in this study. The study period (ranging from 5 to 11 months) was divided into the initial 12 weeks of correction phase and the subsequent maintenance phase. EPO, 1500 U initially, was administered intravenously twice weekly (BIW group, n = 10) or thrice weekly (TIW group, n = 7) at the end of each HD. Dose was doubled every 4 weeks until up to a maximum dose of 6000 U if increment of hematocrit (Hct) was less than 3%. At the end of correction phase, anemia was markedly improved. Hct and hemoglobin (Hb) increased from 19.3 +/- 0.8 to 28.7 +/- 1.1% and from 6.5 +/- 0.3 to 9.6 +/- 0.4 g/dl, respectively. Fifteen patients (88%) reached to the target Hct of 30% at 13.7 +/- 1.2 weeks. At the end of study, Hct and Hb was maintained at 29.1 +/- 0.7% and 9.6 +/- 0.3 g/dl, respectively. Requirement of EPO dose to reach the target and maintain the stable Hct (greater than or equal to 28%) was 99 +/- 14 and 62 +/- 11 U/kg/week, respectively. Laboratory parameters showed that serum iron, transferrin saturation, sugar and triglyceride decreased significantly and uric acid and aluminum (Al) increased significantly. There was no significant change in predialysis blood pressure, body weight, cardiac ratio, and ECG. Quality of life was markedly improved with the better subjective feelings, physical activity and Karnorfsky index. Common adverse effects included exacerbated hypertension (23%), hyperphosphatemia (18%), hyperkalemia (18%), and flu-like syndrome (12%). All of them could be managed by medical and dialysis treatment. Investigation of influencing factors on response to EPO suggests that 1) TIW group had a better response than BIW group 2) Response was better in patients with more adequate iron status and less severe Al burden. 3) Time to target Hct correlated approximately with basal serum Al levels but did not correlate with basal serum parathyroid hormone levels. In conclusion, low dose of EPO therapy corrects anemia effectively with minimal adverse effects in HD patients. Dosing regimen, iron status, and serum Al will influence the response to EPO.

(PDF emailed within 1 workday: $29.90)

Accession: 007120273

Download citation: RISBibTeXText

PMID: 1865507



Related references

Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis. La Pediatria Medica E Chirurgica 13(5): 475-477, 1991

The influence of aluminum and iron status on serum erythropoietin concentrations in hemodialysis patients. Nephrology Dialysis Transplantation 10(6): 1050, 1995

Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis. Casopis Lekaru Ceskych 140(7): 209-213, 2001

Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis. Acta Medica Portuguesa 5(7): 351-357, 1992

Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial. Clinical Laboratory 58(7-8): 737-745, 2012

Effect of aluminum on bioavailability of iron in hemodialysis hd patients treated with recombinant human erythropoietin epo. Clinical & Investigative Medicine 12(SUPPL 4): B66, 1989

Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity. American Journal of Nephrology 18(1): 1-8, 1998

Serum erythropoietin levels in patients with severe anemia secondary to inflammatory bowel disease and the use of recombinant human erythropoietin in patients with anemia refractory to treatment. Diseases of the Colon and Rectum 38(8): 896-897, 1995

Clinical and economical significance of consistent replacement of iron with recombinant human erythropoietin in treatment of anaemia in patients on hemodialysis. Casopis Lekaru Ceskych 140(7): 209-213, 2001

Aluminum interference in the treatment of hemodialysis patients with recombinant human erythropoietin. Nephrology Dialysis Transplantation 5(6): 441-443, 1990

Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. International Journal of Artificial Organs 11(4): 249-254, 1988

The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin. Medicina Clinica 97(18): 687-692, 1991

Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. American Journal of Obstetrics and Gynecology 184(4): 662-667, 2001

Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients. International Journal of Artificial Organs 14(7): 403-406, 1991

Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?. Clinical Nephrology 53(1 Suppl): S23-S29, 2000